CC
KYTX icon

Corton Capital’s Kyverna Therapeutics KYTX Stock Holding History

Corton Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,099
Closed -$45.3K – 440
2024
Q4 		$45.3K Buy
+12,099
New +$58K 0.03% 365

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return

Corton Capital's KYTX Position: Q1 2025 in Review

Corton Capital sold out of Kyverna Therapeutics (KYTX) in Q1 2025, closing a stake of 12,099 shares — an estimated $45.3K sold.

Corton Capital first reported a position in KYTX in Q4 2024 and held it in 1 quarter. The position peaked at $45.3K in Q4 2024. 87 funds tracked by Wall St. Rank hold KYTX as of Q1 2025.

  • Corton Capital reported no remaining Kyverna Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Corton Capital sold 12,099 Kyverna Therapeutics shares in Q1 2025, an estimated $45.3K.
  • Corton Capital first reported a position in Kyverna Therapeutics in Q4 2024 and held it in 1 quarter.
  • Corton Capital's Kyverna Therapeutics position peaked at $45.3K in Q4 2024.
  • 87 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.